Vaccine Preventable Diseases: Adolescents And Adults Global

Vaccine Preventable Diseasesadolescents And Adultsglobal Immunization

Vaccination strategies for adolescents and adults form a critical component of global immunization programs aiming to reduce the burden of preventable diseases. Traditionally, vaccination efforts centered primarily on infants and young children; however, with increasing life expectancy and the recognition that many infectious diseases continue to pose a threat beyond early childhood, immunization policies have expanded to include older populations. The Global Vaccine Action Plan (GVAP) emphasizes extending immunization benefits across all age groups, advocating for innovative delivery methods such as school-based programs and integrating vaccines with other healthcare services for adolescents and adults.

Adolescents, representing over 42% of the world's population, are ideally situated to receive vaccines during routine health visits or school health initiatives. Since many adolescents have already received primary vaccines as children, booster doses or vaccines targeting specific adult diseases can be effectively administered during this life stage. Conversely, the adult population faces unique challenges regarding vaccination uptake. Aging populations are more vulnerable to infectious diseases, with increased severity and risk of complications, especially for those with underlying health conditions. Despite this increased vulnerability, adult vaccination rates remain suboptimal in many regions due to resource constraints, lack of awareness, and missed opportunities within healthcare systems.

The global morbidity and mortality related to vaccine-preventable illnesses underscore their importance. Diseases like hepatitis B and human papillomavirus (HPV) infections cause significant health burdens, including liver cancer and cervical cancer, respectively. Hepatitis B remains highly endemic in regions like the Western Pacific and Africa, where transmission frequently occurs from mother to child during childbirth or through exposure to infected blood in healthcare or community settings. Vaccination against hepatitis B has proven highly effective, with over 95% efficacy in preventing infection and subsequent chronic liver disease. Universal vaccination programs, particularly the timely birth dose, have drastically reduced hepatitis B incidence in many countries.

Similarly, HPV vaccines have transformed the landscape of cervical cancer prevention. Since HPV causes approximately 70% of cervical cancer cases, immunization of preadolescent girls, ideally before sexual debut, is crucial. Countries implementing childhood HPV vaccination see marked reductions in the prevalence of HPV infections and precancerous cervical lesions. The challenge lies in ensuring high coverage rates, particularly in low- and middle-income countries where cervical cancer burdens are disproportionately high. Globally, disparities in vaccination rates continue, driven by socioeconomic factors, limited healthcare infrastructure, and cultural beliefs about vaccines.

The effectiveness of vaccines extends beyond disease prevention; some vaccines prevent infections that lead to cancers such as hepatitis B and HPV. Hepatitis B vaccination, introduced in 1982, has prevented millions of future liver cancer cases, exemplifying how immunization can serve as a cancer prevention strategy. HPV vaccination similarly offers protection against oncogenic strains of the virus, leading to a significant reduction in cervical and other HPV-associated cancers. These successes demonstrate the profound impact of vaccines not only on individual health but also on reducing the global cancer burden.

Addressing vaccine hesitancy and improving coverage among adults remains a pressing challenge. Education and communication strategies from healthcare providers play a vital role in increasing confidence in influenza and other adult vaccines. Providers’ recommendations have consistently been identified as the most influential factor in adults’ vaccination decisions. Emphasizing the safety, efficacy, and importance of vaccines in maintaining health and preventing complications can help overcome misinformation and fears. Additionally, implementing reminder systems and reducing logistical barriers can enhance vaccine uptake in adult populations.

In comparing natural immunity and vaccine-acquired immunity, many experts advocate for vaccination over natural infection due to safety concerns. Natural infection can lead to severe illness, complications, and even death, especially in vulnerable populations. Vaccines offer a safer means of acquiring immunity, mimicking infection without causing disease. Although natural infection may sometimes produce stronger immune responses, the risks involved far outweigh potential benefits. Vaccines provide protective immunity in a controlled manner, with well-documented safety profiles, thus representing a preferable strategy for disease control.

Vaccination coverage varies notably between children and adults. While childhood vaccination programs tend to have higher coverage—due to school entry requirements and focused public health campaigns—adult vaccination rates often lag. Adults are at higher risk of severe outcomes from vaccine-preventable diseases such as influenza, hepatitis B, and pneumococcal disease due to waning immunity, comorbidities, and increased exposure risks. For example, influenza can cause severe complications, including hospitalization and death, particularly among older adults and those with underlying health issues. Therefore, targeted efforts to improve adult immunization are essential to mitigate these risks and protect vulnerable populations.

References

• Bishai, D. M., & Sabarwal, S. (2017). The implications of health system constraints and vaccine hesitancy on achieving immunization coverage targets. Vaccine, 35(12), 1604–1607.
• Centers for Disease Control and Prevention (CDC). (2021). Global Immunization Strategies and Cancer Prevention. MMWR, 70(3), 94–99.
• World Health Organization. (2020). Global health sector strategy on viral hepatitis 2016–2021. WHO Press.
• Garnett, G. P., & Prausnitz, M. R. (2019). HPV vaccines and cervical cancer prevention: Challenges and opportunities. Journal of Cancer Policy, 21, 100220.
• Lund, O., & Østergaard, L. (2018). Immunization strategies for preventing hepatitis B infection. Clinical Infectious Diseases, 66(4), 572–578.
• Bruni, L., et al. (2021). Human papillomavirus and cervical cancer: epidemiology and prevention strategies. Current Oncology Reports, 23(8), 1–14.
• WHO. (2019). Meningococcal meningitis: global burden and vaccination strategies. Weekly Epidemiological Record, 94(16), 161–176.
• Nguyen, D. T., & Le, M. C. (2018). Influenza vaccination in adult populations: Barriers and facilitators. Vaccine, 36(46), 6886–6892.
• Kindig, D. A., & Isham, G. J. (2018). What is population health? American Journal of Public Health, 93(3), 380–383.
• WHO. (2022). Immunization and Vaccine-Preventable Diseases. WHO Fact Sheet.